Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study – Patch.com
By daniellenierenberg
Boca Raton, FL, June 29 Human leukocyte antigens (HLA) diverse genetic markers on our cells that help match patients and donors for bone marrow transplant are the focus of a new study led by the Gift of Life Marrow Registry.
The study, in collaboration with researchers at Rutgers Cancer Institute of New Jersey and the genetic crowd science portal Root, aims to help answer a key question: why do some people get COVID19 or particular symptoms, while others avoid them? More than 350,000 donors in Gift of Life's registry have been invited to participate, helping researchers answer this important question.
"Every volunteer donor is already HLA-typed, presenting a tremendous opportunity to drive broader science through the prism of these immune-related genes," said Gift of Life's Founder and CEO Jay Feinberg. "We're excited to help the world understand how our immune systems may shape the pandemic."
"We hope to learn whether immune-vital tissue match genes such as HLA help explain why some of us avoid COVID-19, while others get severe symptoms or need particular treatments," said the study's principal investigator Jeffrey Rosenfeld, PhD, Assistant Professor of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School. "Adding such key data to the fight against COVID-19, we can help solve the mystery of why it affects different people so differently."
Subscribe
Root's founder, geneticist Nathaniel Pearson, PhD, noted that "because transplant registries read HLA genes better than consumer DNA tests do, a study like this can best reveal how these diverse, immune-vital genes may shape COVID-19. Gift of Life members, who have long saved lives via transplants, now show us how everyday people can help the world beat a pandemic too."
Participants can also opt into short monthly surveys for the coming year, even if they have never had COVID-19. The researchers will study their de-identified data, to better understand how tissue match genes and other factors may figure in COVID-19 risks and outcomes.
Subscribe
The new study furthers Gift of Life's efforts to help people and communities in need during the pandemic. The organization has increased capacity at the Dr. Miriam and Sheldon G. Adelson Gift of LifeBe The Match Collection Center to become a non-hospital based go-to for stem cell donations and contributed 10,000 specialized swabs to Baptist Health South Florida via Boca Raton Regional Hospital to be used for COVID-19 testing.
About Gift of Life Marrow RegistryThe Gift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life or to make a tax-deductible donation, visit http://www.giftoflife.org.
About Rutgers Cancer Institute of New JerseyAs New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.
Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit http://www.cinj.org/giving.
About Root
Root (rootdeep.com) works to grow, diversify, and engage the ranks of blood and marrow volunteers earth's biggest group of living, contactable DNA data owners to save patients in need, honor their good will with good insights, and empower them to spark broader health science discoveries with researchers.
See the article here:
Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study - Patch.com
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Lifestyle UK
By daniellenierenberg
A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.
Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.
Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.
Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.
In total more than 10,000 people were tested across the UK until a match was finally found.
Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour
But just months later, the family faced further anguish after discovering Oscars cancer had returned.
After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.
Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.
Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)
Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.
In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.
Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.
Read more:Woman diagnosed with cancer 48 hours before giving birth
Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.
Out smiles have been growing ever wider as we watched Oscars miraculous journey.
We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.
This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.
Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.
Read more:Parents spot cancer in babys eye after photo taken
Oscar leaves Hospital in Singapore. (SWNS)
Story continues
Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.
His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.
Our future plans now will be to support Oscar and his family and even start some learning at home.
Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.
That will be the best day when he walks back through the door at Pitmaston Primary.
Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)
When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.
A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!
Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes
His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!
Were actually bringing him home!!!
You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.
Enjoy every last minute of this journey darling, because YOU have owned [sic] it!
Additional reporting SWNS.
See the article here:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Lifestyle UK
CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients -…
By daniellenierenberg
VANCOUVER, Washington, June 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn” or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company and the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals of Mexico (NIH) have entered into a Memorandum of Understanding (MOU) to conduct a COVID-19 clinical trial with leronlimab for severe and critically ill patients, with the potential to collaborate on additional COVID-19 trials. The NIH of Mexico is an organization that coordinates the main institutions of medical care and public research in the country.
The MOU provides CytoDyn will supply leronlimab at its expense to the NIH and both parties are proceeding forward expeditiously to complete the mutually agreed protocol for this clinical trial.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented: We are very pleased with the confidence demonstrated by the NIH of Mexico in our drug, leronlimab, and we are both very motivated to initiate this trial quickly to help mitigate the devastation of the COVID-19 pandemic on the citizens of Mexico. The anecdotal data received by CytoDyn (from over 70 COVID-19 critical patients who were treated under EIND in the U.S.) has impressed the NIH of Mexico and we believe with a small Phase 3 trial of only 25 patients, leronlimab could receive approval in Mexico very quickly. This Phase 3 trial is similar to our Phase 3 trial protocol in the U.S., with the exception of the number of patients.”
About Coronavirus Disease 2019 CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy The FDA has granted a Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the FDA deems a BLA submission complete, it sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA. The Company filed a request for Priority Review designation for its BLA to shorten the FDA’s review time from 10 to 6 months, an FDA goal for BLA applications given Priority Review designation.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug” designation to leronlimab for the prevention of GvHD.
About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.
Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes,” hopes,” intends,” estimates,” expects,” projects,” plans,” anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.
CYTODYN CONTACTS Investors: Cristina De Leon Office: 360.980.8524, ext. 106 Mobile: 503.214.0872 cdeleon@cytodyn.com
Go here to read the rest:
CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients -...
COVID threat isnt over, especially for Coloradans with chronic conditions – The Denver Post
By daniellenierenberg
The COVID-19 pandemic has been a shock for most people, but for Clay Drake, much of it was familiar: the need to stay in, the stocking up on hand sanitizer, the concern that a simple trip to church could turn deadly.
Drake, of Windsor, has multiple myeloma, a blood cell cancer, and underwent two stem cell transplants that knocked out his immune system for months. A bout with the seasonal flu lasted more than a month, and for a while he was getting colds that took him weeks to shake, he said.
That was my COVID, he said. I spent probably about a year doing what everybody started doing in March.
While many though not all healthy people who get COVID-19 can recover at home, those who have chronic conditions are six times as likely to be hospitalized and 12 times as likely to die, according to a report from the Centers for Disease Control and Prevention.
Drake still gets chemotherapy and immunotherapy treatments to keep the cancer in remission. Because of the heightened risk from infections, he tries to minimize trips to crowded places but has started seeing small groups of friends again and occasionally eating out. Most people around Windsor seem to be wearing masks and following other recommendations, which makes it safer, he said.
For the most part, I feel comfortable going out in public, he said.
People who have chronic conditions need to be vigilant about social distancing, wearing a mask and washing their hands, according to the CDC, and should talk to their doctors about additional precautions.
While those who know they face a higher risk of dying can take some steps to protect themselves, the rest of the community also needs to help keep the virus from breaking out, said Dr. Peter Buttrick, a cardiologist and member of the board for the Denver branch of the American Heart Association. Most people who get the virus can spread it before developing symptoms, meaning they could inadvertently give it to someone whos at a higher risk especially if they arent wearing masks, he said.
The likelihood youll be in contact with someone who is infected and asymptomatic is higher when theres ongoing community spread, he said.
Colorados new cases are down from a peak in April, but theyve started to tick back up and Gov. Jared Polis has urged the public to continue avoiding large events and wearing masks.
The Centers for Disease Control and Prevention released an updated list Thursday of the clearest risk factors for getting severely sick or dying from COVID-19:
The CDC also listed other conditions as possible risk factors, though the evidence is mixed or from small studies:
A large study in the United Kingdom found that the risk of dying increased sharply with age, but younger people were also at a higher risk if they had certain conditions, said Dr. Jonathan Samet, dean of the Colorado School of Public Health. Diabetes and chronic lung conditions such as emphysema roughly doubled the risk of dying compared to a healthy person of the same age, and heart disease increased the risk by about 25%. Obesity also raised a persons risk of complications, he said.
About 7% of adults in Colorado have diabetes and 23% have obesity, which are some of the lowest rates in the country, according to Americas Health Rankings. Still, that means thousands of people are at an elevated risk, and not all of them may have the ability to stay at home. Ideally, those who are at a high risk would continue social distancing at a high level, Samet said.
Its certainly a time for caution, if peoples jobs and lives allow it, he said.
Not everyone with diabetes is at an equal risk, said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. People who have poorly controlled blood sugar and have other chronic conditions generally are at a higher risk from infections, including COVID-19. That makes it important to keep in touch with your doctor and to manage your diabetes well, he said.
If you have diabetes, you have high blood sugars, youre obese and you have maybe cardiovascular disease, youre at high risk and you need to be really careful, he said, adding that age also is a factor to consider.
Its not entirely clear why certain conditions are linked to a higher risk of complications. One possibility is that when hearts are stressed by high blood pressure or coronary artery disease, their cells produce more of certain receptors that the virus binds to though more research is needed to understand if thats the issue, Buttrick said. He urged people not to put off seeking medical advice if they have symptoms that could suggest heart trouble, such as chest pain, shortness of breath, heart palpitations or fainting not only because of the virus risk, but also because the problem itself may need immediate treatment.
Heart disease doesnt go on vacation during the pandemic, he said.
Buttrick and Samet dont advise people with chronic illnesses to stay at home at all times, but say they should consider ways to avoid crowds, like visiting the grocery store during hours set aside for high-risk customers. Ultimately, each patient and doctor need to discuss individual risks, though.
Im telling all of my patients, and I think everybody is, that if youre of a certain age, you need to be really careful, Buttrick said.
People with diabetes and other conditions have to consider their individual level of risk, as well as how risky any particular activity is, Gabbay said. If you have well-controlled blood sugar and no other chronic conditions, you might feel more comfortable going to a lower-risk social event, while someone whose health is more precarious might avoid any exposure that isnt absolutely necessary.
Thats whats made this so difficult there are no hard and fast rules, he said.
Hyoung Chang, The Denver Post
Drake, who volunteers with the American Cancer Society, said he sometimes gets calls from people trying to figure out what they should do, and he steers them toward the ACS guidelines. Some of them are particularly worried about how to move forward with cancer treatment during a pandemic, he said.
I feel like theres a lot of people, particularly the more susceptible and elderly, who are scared, he said.
Subscribe to bi-weekly newsletter to get health news sent straight to your inbox.
Visit link:
COVID threat isnt over, especially for Coloradans with chronic conditions - The Denver Post
HRMC to open hematology and oncology clinic – The Ottawa Herald
By daniellenierenberg
On Aug. 4, Hutchinson Regional Medical Center will open the Hutchinson Hematology and Oncology clinic. Dr. Sawsan Amireh will join the Hutch Regional team that day and see her first patients at her clinic which will be located in Suite 4 of Doctors Park at 2100 N. Waldron St., a building located to the southwest of the main hospital campus on the east side of Waldron Street.
Hematology and Oncology are two branches of medicine that continue to be a concern of members of our community and throughout the State of Kansas.
Oncology is the branch of medical science dealing with tumors, including the diagnosis and treatment of cancer. More than 1.8 million Americans, including 16,000 Kansans, are diagnosed with cancer each year. For more than 600,000 of our nations population each year, cancer is a terminal disease. The good news is that 17 million Americans are living out their lives as cancer survivors.
Cancer is best defined as the uncontrolled growth and spread of abnormal cells and the cause is often attributed to everything from heredity to an unhealthy lifestyle including tobacco use and excess weight. Treatments are medical, surgical, Chemotherapy and Radiation.
Hematology is the branch of medicine dealing with the cause, treatment and prevention of disease related to the blood. Specific issues dealt with include treatment of bleeding disorders, Lymphoma and Leukemia and blood transfusions, along with bone marrow and stem cell transplants.
Dr. Amireh, who has received training on the latest treatment protocols, arrives at Hutch Regional with impeccable credentials and is Board Certified in Internal Medicine. She received her doctorate degree in 2011 from the University of Jordan School of Medicine in Amman, Jordan. Since 2017, Dr. Amireh has participated in a Hematology and Oncology Fellowship and also served as chief fellow with the State University of New York Downstate Health Science Center in Brooklyn, New York. Also, Dr. Amireh served as Associate Chief Medical Resident and Internal Medical Resident at Saint Michaels Medical Center in New Jersey.
In 2010, Dr. Amireh completed special training at Vanderbilt University Medical Center in Nashville, Tennessee on Hepatology and Pediatric Endocrinology. She has won numerous awards and honors including the Clinical Documentation Excellence Award from St. Michaels Medical Center, the Academic Excellence Award from the University of Jordan School of Medicine, and the English Talented Writing Award from the University of Jordan.
Dr. Amireh is a member of the American Society of Clinical Oncology, American Society of Hematology, American College of Physicians, and the Jordan Medical Association.
Dr. Amireh said Oncology has entered a new era with the onset of COVID-19. "Cancer patients are now more vulnerable and will need to be more diligent to avoid infection which proves that life is more fragile than it once was," Dr. Amireh said. "I am looking forward to starting a hospital-based practice. We have a young family and southcentral Kansas is a good place to raise a two-year old. New York is too busy and not really family friendly."
"I want my practice to be inclusive and will welcome everyone who needs treatment and care," Dr. Amireh continued.
Appointments with Dr. Amireh will be accepted starting in Mid-July. Additional information including her clinics contact information will be published at that time.
With the opening of Hutchinson Hematology and Oncology, south central and western Kansas will have a new choice for quality cancer care. Dr. Amireh will provide a caring, personal approach to cancer care and her clinic will work in tandem with the Chalmers Cancer Center and the other Hutchinson Regional Healthcare System entities as well as other physician specialties in Hutchinson and surrounding communities to provide an integrated approach to care in Hutchinson.
Dr. Amireh will join her spouse, Dr. Mohammed "Mo" Al-Halawani at Hutch Regional. In July 2019, Dr. Al-Halawani joined Dr. Tariq Musa in opening Hutchinson Pulmonology Associates at Hutchinson Regional Medical Center. Dr. Al-Halawani and Dr. Musa hit the ground running and are serving patients in Hutchinson as well as an outreach clinic in McPherson, with plans to support pulmonary needs locally and in the surrounding areas.
We are excited that these high caliber healthcare professionals have chosen to move across America to provide their expertise to residents on the plains of Kansas.
Ken Johnson is the President and CEO of Hutchinson Regional Medical Center.
Continue reading here:
HRMC to open hematology and oncology clinic - The Ottawa Herald
Sickle Cell Disease: All you need to know – The Indian Express
By daniellenierenberg
By: Lifestyle Desk | New Delhi | Updated: June 27, 2020 12:09:31 pm Heres everything to know about the blood disorder. (Source: Getty Images/Thinkstock)
Sickle cell disease (SCD) is an inherited group of blood disorder which is genetic in nature. It is usually transferred from parents to the child during birth i.e. both the parents can be carries of SCD. Healthy RBCs are round in shape, which moves through small blood vessels and carries oxygen to all parts of the body. In someone who has SCD, the RBC becomes sticky and hard and start to look like C- shaped similar to that of a farm tool sickle. The sickle cells die early, which causes a constant shortage of RBC, which leads to low oxygen carriers in the body, mentioned Dr Rahul Bhargava, director and head, haematology and bone marrow transplant, Fortis Memorial Research Institute, Gurugram. Also, when sickle cells travels they tend to get stuck in small blood vessels and restrict the blood flow. This can cause pain in the joints, chest and other serious problems such as stroke, acute chest syndrome and infections.
Anaemia
SCD can lead to shortage of RBC which makes the patient anaemic. It can lead to less oxygen supply in the body causing fatigue.
Episodes of pain. SCD patients suffer from episodes of periodic pain. Sickle-shaped blood cells can block the flow of blood which in tiny vessels of abdomen, chest and joints, thus leading to pain.
Feet and hands swelling
Sickle-shaped RBC can block then flow of blood which can cause swelling in the hands and feet.
Frequent infections
Sickle cells can damage the spleen and make the person vulnerable to diseases and infections. Vaccination is usually prescribed in childhood to keep infections at bay.
Delayed growth or puberty
RBC is the carrier of oxygen and other nutrients. With low RBC, there is no enough oxygen in the body which can slow the growth in infants and children which leads to delayed puberty in children.
Vision problems
Vision is affected when the flow of blood is affected.
SCD can lead to a lot of complication, including Stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers and more such complications.
SCD can be diagnosed with a simple blood test. Parents are advised to get the screening done before conceiving as it is transmitted from parents. For newborns, the test is done in the hospitals as a routine screening. There is no single treatment for SCD patients and it varies from patient to patient on the basis the symptoms. Before starting any medication, consult a haematologist who specialises in blood disorders.
The only cure for SCD is getting a bone marrow transplant (BMT), which is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Stem cells are easily taken from the donor and planted in the recipient. After the BMT procedure, the patient can lead a healthy and normal life.
The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
For all the latest Lifestyle News, download Indian Express App.
IE Online Media Services Pvt Ltd
Read more:
Sickle Cell Disease: All you need to know - The Indian Express
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Singapore News
By daniellenierenberg
A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.
Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.
Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.
Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.
In total more than 10,000 people were tested across the UK until a match was finally found.
Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour
But just months later, the family faced further anguish after discovering Oscars cancer had returned.
After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.
Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.
Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)
Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.
In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.
Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.
Read more:Woman diagnosed with cancer 48 hours before giving birth
Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.
Out smiles have been growing ever wider as we watched Oscars miraculous journey.
We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.
This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.
Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.
Read more:Parents spot cancer in babys eye after photo taken
Oscar leaves Hospital in Singapore. (SWNS)
Story continues
Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.
His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.
Our future plans now will be to support Oscar and his family and even start some learning at home.
Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.
That will be the best day when he walks back through the door at Pitmaston Primary.
Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)
When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.
A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!
Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes
His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!
Were actually bringing him home!!!
You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.
Enjoy every last minute of this journey darling, because YOU have owned [sic] it!
Additional reporting SWNS.
View original post here:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Singapore News
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Canada Sports
By daniellenierenberg
A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.
Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.
Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.
Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.
In total more than 10,000 people were tested across the UK until a match was finally found.
Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour
But just months later, the family faced further anguish after discovering Oscars cancer had returned.
After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.
Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.
Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)
Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.
In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.
Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.
Read more:Woman diagnosed with cancer 48 hours before giving birth
Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.
Out smiles have been growing ever wider as we watched Oscars miraculous journey.
We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.
This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.
Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.
Read more:Parents spot cancer in babys eye after photo taken
Oscar leaves Hospital in Singapore. (SWNS)
Story continues
Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.
His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.
Our future plans now will be to support Oscar and his family and even start some learning at home.
Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.
That will be the best day when he walks back through the door at Pitmaston Primary.
Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)
When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.
A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!
Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes
His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!
Were actually bringing him home!!!
You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.
Enjoy every last minute of this journey darling, because YOU have owned [sic] it!
Additional reporting SWNS.
Read this article:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Canada Sports
Recovering from Cancer, a Stem Cell Transplant and Coronavirus – Cancer Health Treatment News
By daniellenierenberg
Dana-Farber Patient Recovering Well After Cancer and the Coronavirus
Pam Dobay is a warrior. In the last three years, the 67-year-old has dealt with a cancer diagnosis and stem cell transplant before recently contracting the coronavirus.
None of it was easy, but today, Dobay is recovering at home. She says she cannot begin to express the gratitude she feels towards everyone who has cared for her, including her Dana-Farber care team and her family.
When this is all over, I want to show everyone at Dana-Farber what they did, and thank them for everything, says Dobay.
A Blood Cancer Diagnosis
In February 2018, Dobay was diagnosed with myelofibrosis, a blood disorder in which the bone marrow is unable to produce healthy red blood cells. Dobays primary care physician first worried something wasnt right after her test results from routine blood work came back abnormal. Myelofibrosis is a precursor condition for leukemia, meaning it puts those who are diagnosed at a much higher chance of developing the disease.
Dobay, who lives in Holbrook, MA, was placed under the care ofCorey Cutler, MD, MPH, medical director of theAdult Stem Cell Transplantation Programat Dana-Farber/Brigham and Womens Cancer Center. Initially, she was given blood transfusions to help her body compensate for the bone marrows inability to produce red blood cells. This treatment is not designed to be a permanent fix, despite being highly effective for a short period of time: Eventually, Dobay would need a bone marrow transplant.
In September 2018, just six months after her diagnosis, Dobay underwent areduced-intensity transplant(sometimes referred to as a mini-transplant). Mini-transplant patients receive lower doses of chemotherapy than are used in a full-intensity transplant, and in general, receive no radiation therapy. The reduced-intensity procedure was developed for older patients and others who often cant tolerate the harsh side effects of full-intensity treatments.
The procedure still proved to be difficult for Dobay, who ended up in the intensive care unit (ICU) due to complications. This was a possibility her care team had prepared for, and slowly, her condition improved. While she still has some symptoms of chronic graft-versus-host disease (GVHD), she and her family including Robert Dobay, her husband of 45 years hoped this would be her toughest test.
This article was originally published on June 18, 2020, by Dana-Farber Cancer Institute. It is republished with permission.
View original post here:
Recovering from Cancer, a Stem Cell Transplant and Coronavirus - Cancer Health Treatment News
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 – 3rd Watch News
By daniellenierenberg
The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.
The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).
Regional Overview:
The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.
Australia, New Zealand, Rest of Asia-Pacific
The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21
The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.
Cell Therapy ManufacturingMarket Key Companies:
harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.
The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.
Segmentation Overview:
The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.
Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21
Key Questions Answered in Report:
Stakeholders Benefit:
Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21
About us:
Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.
Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +1 860 531 2701
Email: [emailprotected]
VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622
Read the original post:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News
5-year-old Thai boy with COVID-19 saves sisters life with his stem cells – Yahoo Singapore News
By daniellenierenberg
One day before Sila Jio Boonklomjit was set to donate desperately needed stem cells to save his sisters life, doctors made an alarming discovery: Hed contracted COVID-19.
The 5-year-old COVID-19 patient is now being credited with saving his big sisters life by going through with an experimental procedure to cure her of a genetic blood disorder without passing along the coronavirus.
Saying it was the first known case of such a procedure, Ramathibodi Hospital claimed victory yesterday after successfully transplanting bone marrow from Jio to his sister, Jintanakan Jean Boonklomjit, who was born with thalassemia and was in a severe condition.
Its as if my daughter is reborn and gets a new life, said the childrens father, Suchai Boonklomjit.
Thalassemia is a hereditary disorder that limits the bloods ability to carry oxygen and affects an estimated 1% of all Thais. Rather than being treated by ongoing blood transfusions, recent breakthroughs have shown it can be cured through gene therapy.
The procedure began in April but wasnt completed until yesterday by Suradej Hongeng of the hospitals pediatrics department.
Posted by onTuesday, June 23, 2020
According to Suradej, it was a long and uncertain road to this happy outcome. It had been difficult to find a donor compatible with Jean, leading them to settle on Jio as her best hope. After they were confirmed to be a genetic match in 2018, they prepared for the transplantation procedure.
Other difficulties followed, in part due to the young age of both patients. Moreover, Jeans immune system was compromised by chemotherapy while Jio had to be placed in quarantine on the eve of the procedure. Doctors believe he was likely infected by his mother, Sasiwimol Boonklomjit.
The case is believed to be the first successful stem cell transplant from a donor with active COVID-19. Both Jio and his mother have since recovered from the virus.
Read more of Coconuts Bangkoks content here.
This article, 5-year-old Thai boy with COVID-19 saves sisters life with his stem cells, originally appeared on Coconuts, Asia's leading alternative media company. Want more Coconuts? Sign up for our newsletters!
Read more:
5-year-old Thai boy with COVID-19 saves sisters life with his stem cells - Yahoo Singapore News
Hematopoietic Stem Cell Transplantation (HSCT) Market Expand Their Businesses With New Investments In 2020 And Coming Future – Bulletin Line
By daniellenierenberg
Hematopoietic Stem Cell Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cell Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cell Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cell Transplantation (HSCT) sales, revenue and market share for each player covered in this report.
Key Target Audience of Hematopoietic Stem Cell Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cell Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cell Transplantation (HSCT) market.
Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986
Synopsis of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).
Based onProduct Type, Hematopoietic Stem Cell Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:
Allogeneic Autologous
Based onend users/applications, Hematopoietic Stem Cell Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:
Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)
Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:
Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986
The Hematopoietic Stem Cell Transplantation (HSCT) Market Report Can Answer The Following Questions:
What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cell Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cell Transplantation (HSCT)?
Who are the key manufacturers of Hematopoietic Stem Cell Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?
Economic impact on Hematopoietic Stem Cell Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cell Transplantation (HSCT) industry.
What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cell Transplantation (HSCT)?
What will the Hematopoietic Stem Cell Transplantation (HSCT) Market Size and The Growth Rate be in 2026?
What are the key market trends impacting the growth of the Hematopoietic Stem Cell Transplantation (HSCT) market?
What are the Hematopoietic Stem Cell Transplantation (HSCT) Market Challenges to market growth?
What are the types and applications of Hematopoietic Stem Cell Transplantation (HSCT)? What is the market share of each type and application?
What are the key factors driving the Hematopoietic Stem Cell Transplantation (HSCT) market?
What are the Hematopoietic Stem Cell Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cell Transplantation (HSCT) market?
Contact:
ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]
Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/
Read the original post:
Hematopoietic Stem Cell Transplantation (HSCT) Market Expand Their Businesses With New Investments In 2020 And Coming Future - Bulletin Line
Should You Delay Cancer Treatment Because of COVID-19? Study Says Most Treatments Dont Worsen Coronavirus Infection – On Cancer – Memorial Sloan…
By daniellenierenberg
Summary
A review of 423 patients treated at MSK finds that most people with cancer dont fare any worse if they get COVID-19 than other people who are hospitalized for that infection.
In the early days of the COVID-19 pandemic, many doctors worried that people undergoing treatment for cancer would do particularly poorly if they became infected with the virus that causes the disease. Thats because treatments for cancer, especially chemotherapy, can lower a persons immune defenses and put them at higher risk for all kinds of infections.
But according to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, most people in active cancer treatment dont fare any worse if they get COVID-19 than other people who are hospitalized with the infection. Further research is needed to look at the effects of certain drugs mainly immunotherapies called checkpoint inhibitors, which did seem to make COVID-19 worse. But the researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.
If youre an oncologist and youre trying to figure out whether to give patients chemotherapy, or if youre a patient who needs treatment, these findings should be very reassuring, says infectious disease specialist Ying Taur, one of the studys two senior authors.
Infectious disease expert Ying Taur has cared for many MSK patients who were hospitalized with COVID-19.
The study looked at 423 MSK patients diagnosed with COVID-19 between March 10 and April 7, 2020. Overall, 40% were hospitalized for COVID-19, and 20% developed severe respiratory illness. About 9% had to be placed on a mechanical ventilator, and 12% died. The investigators found that patients taking immunotherapy drugs called immune checkpoint inhibitors were more likely to develop severe disease and require hospitalization. But other cancer treatments, including chemotherapy and surgery, did not contribute to worse outcomes.
The big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.
Factors that did make COVID-19 worse were the same as those seen in studies of people who didnt have cancer. We found that being older, as well as preexisting conditions like heart disease and diabetes, are all drivers of severe COVID-19 illness, says MSK Chief Medical Epidemiologist Mini Kamboj, the studys other senior author. This wasnt surprisingbecause these connections are well established.
Although the study wasnt large enough to make determinations about every treatment and every cancer type, patterns did emerge. Dr. Taur says there was initially great concern about people receiving high doses of chemotherapy for leukemia, especially those who had recently undergone bone marrow or stem cell transplants. Thats because transplants require a persons entire immune system to be wiped out with chemotherapy before they receive new blood cells, leaving them susceptible to all kinds of infections.
Surprisingly, though, Dr. Taur cared for recent transplant recipients who were infected with COVID-19 but didnt have any symptoms. If you think about it more, it makes sense, he says. Most of the complications seen in people with COVID-19 seem to be caused by the bodys immune response to the virus.
On the other hand, immunotherapy drugs called checkpoint inhibitors work by freeing up the immune system to attack cancer. Patients receiving these agents may develop a more robust reaction to the virus that causes COVID-19. This may explain why this study observed higher rates of complications in people with COVID-19 infection who were treated with checkpoint inhibitors.
Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them, Dr. Kamboj says. Its just important for doctors to be extra vigilant about testing and monitoring for the virus and for people with cancer to take extra precautions to avoid infection.
A study published in May 2020 by MSK immunotherapy expert Matthew Hellmann focused exclusively on people with lung cancer who got COVID-19. The researchers didnt find the same risks from immune checkpoint drugs as this Nature Medicine study. But that study included data on far fewer patients treated at MSK, which could explain the difference.
Dr. Kamboj notes that one aspect of this research that sets it apart from other studies is that it included at least 30 days of follow-up after a COVID-19 diagnosis. Also, it reported severe respiratory illness as a main outcome rather than death.
Having that follow-up time is something that a lot of other studies have not included because everyone is in a rush to get their data out. In addition, reporting death rates can overestimate infection-related mortality, especially in the early phase of an epidemic, Dr. Kamboj says. Also, the clinical spectrum and course of this disease is still not fully understood, especially in people with cancer. We wanted to give patients enough time to recover and make sure they didnt need to be readmitted to the hospital.
Even with immune checkpoint inhibitors, though, these findings should not affect whether patients get treated. Everyone who needs these drugs should still receive them.
She adds that another strength of the study is that patient outcomes were not affected by constraints caused by a lack of space or supplies even though MSK is in the heart of the COVID-19 epicenter in New York City, where other hospitals faced overcrowding and other issues. This gave researchers a true picture of how cancer patients fare with COVID-19. We saw a surge during the peak of the epidemic in New York, but everyone got the care they needed, Dr. Kamboj explains. We had enough ventilators for everyone who needed them. We never had to make decisions about who to admit to intensive care because of a lack of critical equipment.
Drs. Taur and Kamboj agree that this is just one of many studies that will need to be done on the connections between cancer and COVID-19. We still need to find out more. We need to look at the connections between COVID-19 and particular types of cancer as well as outcomes related to specific chemotherapy drugs, Dr. Taur concludes. But the big message now is clear: People should stay vigilant but not stop or postpone checkpoint immunotherapy or any other cancer treatment.
Bone Marrow Processing Systems Market Business Analysis, New Innovation | Share, Revenue, And Sales Till 2025 – Cole of Duty
By daniellenierenberg
Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.
Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3184
The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.
In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.
Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.
Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others
Covid 19 Impact[emailprotected] https://www.trendsmarketresearch.com/report/covid-19-analysis/3184
See the rest here:
Bone Marrow Processing Systems Market Business Analysis, New Innovation | Share, Revenue, And Sales Till 2025 - Cole of Duty
TP53, KMT2D Abnormalities Linked With Poor Prognosis in MCL – Targeted Oncology
By daniellenierenberg
Disruption of the TP53 gene and mutation of the KMT2D gene are predictive of poor outcomes in patients with mantle cell lymphoma (MCL) who are receiving high-dose therapy, according to a new study.
The findings, which build upon growing knowledge of the genetics of MCL, can be used to better classify patients into risk categories, the investigators said. The study was published in the journal Haematologica.1
Corresponding author Simone Ferrero, MD, of the University of Torino, in Italy, noted that the current treatment paradigm for patients with MCLcytarabine-based chemotherapy followed by autologous stem cell transplantation (ASCT)has led to dramatic advancements in the outcomes of patients who are young and healthy enough for the therapy. However, Ferrero said as many as one-quarter of those patients will experience early treatment failure.
So far, the best tool clinicians have had to identify patients at high risk of relapse has been the MCL international prognostic index (MIPI), and the Ki-67 proliferation index. The combination of the 2 is known as the MIPI-c score. Although the tool is of value, Ferrero and colleagues asserted that the resulting scores lack the precision necessary to develop tailored schedules specifically for high-risk patients.
In an effort to better elucidate the factors associated with a high risk of failure, the investigators used samples from the phase III FIL-MCL0208 trial, which is a prospective, open-label, multicenter study designed to evaluate lenalidomide (Revlimid) as a maintenance therapy versus observation in patients in MCL remission following high-dose chemotherapy including rituximab (Rituxan) followed by ASCT (NCT02354313).
Ferrero and colleagues performed targeted resequencing and DNA profiling on purified tumor samples of the patients in the study. Out of 300 patients enrolled in the study, samples from 186 patients were able to be evaluated for genetic mutations and abnormalities in copy numbers.
The analysis confirmed earlier reports2,3 that TP53 disruption is a significant prognostic factor. After 4 years, patients with mutations or deletions of TP53 had lower progression-free survival (PFS) and overall survival (OS) rates compared with patients without the disruptions.
However, the authors broke new ground by identifying KMT2D as another important genetic factor. In wild-type cases, those with KMT2D mutations had PFS rates of just 33.2%, versus 63.7% in those without the mutation after 4 years (P <.001). Overall survival was similarly affected; the 4-year OS rate among patients with KMT2D mutations was 62.3% versus 86.8% among those without the mutation (P = .002).
In the FIL-MCL0208 trial, KMT2D mutations emerged as a novel biomarker heralding chemo-immunotherapy failure, with a predictive value similar to that of TP53 aberrations, Ferrero and colleagues wrote.
The authors then used their findings to create a new scoring system to identify patients at the highest risk.
The independent adverse prognostic value of TP53 and KMT2D aberrations prompted us to integrate the molecular results into the MIPI-c, aiming at further improving its ability to discriminate high-risk patients, the authors said.
The model begins with MIPI-c score; those with low or intermediate risk scores under MIPI-c were given 0 points in the new model, and those placed in the high-risk category by the MIPI-c model were given one point. In addition, patients with TP53 disruptions were given 2 additional points, as were those with the KMT2D mutation. In this new scoring system, which the investigators dubbed MIPI-g, patients with a score of 0 were deemed low risk, patients with scores of 1 to 2 were deemed intermediate risk, and patients with scores of 3 or higher were categorized as high risk.
When investigators performed PFS and OS calculations based on their risk categories, they found PFS rates varied dramatically among the groups, from 72.0% in the low-risk group to 11.5% in the high-risk group after 4 years (P <.0001). Four-year OS rates similarly dropped from 94.5% in the low-risk group to 44.9% (P <.0001). Among patients in the intermediate group, the 4-year PFS rate was 42.2% and the OS rate was 65.8%.
In the Nordic validation series, patients with KMT2D mutations showed similar worse outcomes compared with wild-type patients (median OS, 8.4 vs 12.7 years). Among patients with TP53 mutations, the median OS was 2.0 years compared with 12.7 years for patients with wild-type TP53. The validation series also showed similar 4-year OS rates by risk groups: 91.3% for low-risk patients, 72.2% for intermediate risk, and 15.4% for high risk.
Among the studys limitations, the authors noted that their analysis was performed only on CD19-positive bone marrow cells. The investigators also said they do not yet have sufficient randomization data to know whether and to what extent lenalidomide maintenance affected the patients with these mutations within the broader FIL-MCL0208 trial. However, they said it is unlikely that full data will be able to offer clear takeaways, since only 27 patients with the TP53/KMT2D mutations were finally randomized in the study, due to a high rate of progressive disease among these patients. Of those 27, only 9 were started on lenalidomide maintenance.
In their conclusion, Ferrero and colleagues said that the ability to distinguish the highest-risk patients could be used by clinicians to identify high-risk patients for novel therapeutic approaches.
As in other lymphoid disorders, novel non-chemotherapeutic strategies specifically designed for [high-risk] patients need to be investigated in MCL, the authors said. Besides the approved drugs lenalidomide and ibrutinib [Imbruvica], new molecules such as the BCL-2 inhibitor venetoclax [Venclexta] might be very promising for these chemorefractory patients, especially for TP53 disrupted cases.
References:
1. Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105(6):1604-1612. doi:10.3324/haematol.2018.214056
2. Nordstrm L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogeneously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Br J Haematol. 2014;166(1):98-108. doi:10.1111/bjh.12854
3. Halldrsdttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011;25(12):1904-1908. doi:10.1038/leu.2011.162
See the rest here:
TP53, KMT2D Abnormalities Linked With Poor Prognosis in MCL - Targeted Oncology
Bone Marrow Processing Systems Market Insights on Challenges & Opportunities by 2025 – 3rd Watch News
By daniellenierenberg
Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.
Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3184
The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.
In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.
Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.
Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others
Covid 19 Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/3184
See the article here:
Bone Marrow Processing Systems Market Insights on Challenges & Opportunities by 2025 - 3rd Watch News
Stem Cell Banking Market Report (2020-2025) | The Demand For The Market Will Drastically Increase In The Future – Jewish Life News
By daniellenierenberg
The global Stem Cell Banking market was valued at USD 1.52 billion in 2016 and is projected to reach USD 7.94 billion by 2025, growing at a CAGR of 20.17% from 2017 to 2025.
View Source Of Related Reports:
Viral Inactivation MarketVirus Filtration MarketViral Clearance MarketVeterinary-Animal Vaccines Market Vaccine Adjuvants MarketTerahertz and Infrared Spectroscopy MarketTangential Flow Filtration MarketSterile Filtration MarketStem Cell Banking Market
Stem Cell banking involves preservation of new born placental stem cells or amniotic stem cells as well as adult bone marrow stem cells. The concept ensures health safety in case of a major surgery or organ regeneration needs for the patient. With increasing awareness regarding the practice, the market is expected to boost in near future.
The Final Report will cover the impact analysis of COVID-19 on this industry:
Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10008449
Sample Infographics:
Market Dynamics:1. Market Drivers1.1 Easy Extraction Methods1.2 High birth ratio1.3 Increase in GDP and Disposable income in developing nations1.4 Increasing support from public and private sector1.5 Scope of stem cell usage in therapeutics and treatment2. Market Restraints2.1 Large number of players in the market2.2 High Cost of technology2.3 Lack of awareness2.4 Regulatory restrains
Market Segmentation:1. By Application:1.1 Cerebral Palsy1.2 Thalassemia1.3 Leukemia1.4 Diabetes1.5 Autism1.6 Others
2. By Services:2.1 Collection & Transportation2.2 Processing2.3 Analysis2.4 Storage
3. By Bank Type:3.1 Cord Blood3.2 Cord Tissue
4. By Region:4.1 North America (U.S., Canada, Mexico)4.2 Europe (Germany, UK, France, Rest of Europe)4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)4.4 Latin America (Brazil, Argentina, Rest of Latin America)4.5 Middle East & Africa
Competitive Landscape:The major players in the market are as follows:1.CBR Systems, Inc.2. Cordlife3. Cryo-Cell4. Cryo-Save AG (A Group of Esperite)5. Lifecell6. Stemcyte7. Viacord8. Smart Cells International Ltd.9. Cryoviva India10. Cordvida11. China Cord Blood CorporationThese major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
Request For Full Report:https://www.kennethresearch.com/sample-request-10008449
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:Research study on the Stem Cell Bankingmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
About Kenneth Research:
Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.
Contact Us
Kenneth Research
Email:[emailprotected]
Phone: +1 313 462 0609
Originally posted here:
Stem Cell Banking Market Report (2020-2025) | The Demand For The Market Will Drastically Increase In The Future - Jewish Life News
Acute Myeloid Leukemia (AML) Therapeutics Market Promising Growth Opportunities over 2017 2025 – 3rd Watch News
By daniellenierenberg
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. Leukemia can grow along either the myeloid or lymphoid stem cell lines, it depends on the effect of genetic and epigenetic mutations on the progression of pluripotent stem cells to the various lines of mature cells which then pass into the blood. The effected line, combined with the rate of action and growth of disease reflects the four types of leukemias- Acute Myeloid Leukemia (AML), chronic lymphoblastic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia. AML: Acute Myeloid Leukemia, is a serious condition, its the most common leukemia suffered by adult people. According to a report from American Cancer Society, the average age for first diagnostic for AML is 64. With few days without treatment, AML develops fast, in duration of few weeks, the patient becomes severely ill. Due to its fast onset and acuteness in nature, there is no staging system for Acute Myeloid Leukemia (AML).The treatment for Acute Myeloid Leukemia (AML) has changed in last 4 decades.
Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/16738
The drug approval process is difficult in AML, (many drugs have not been approved by USFDA, for instance Laromustine, Dacogen and Tipitarnib) efforts have been made to introduce new therapies in the AML market.
Primary drivers boosting the growth of acute myeloid leukemia (AML) therapeutics market are minimal but increased prevalence of acute myeloid leukemia (AML), increased drug approval rate for AML, classification of acute myeloid leukemia (AML) as an orphan disease. Over the forecast period, population of people over 65 year is anticipated to increase, which is another key driver for acute myeloid leukemia (AML) therapeutics market.
However, lack of targeted therapies in current acute myeloid leukemia (AML) therapeutics landscape, the drug difficult approval process in AML can hinder the growth of acute myeloid leukemia (AML) therapeutics market, but this restraint has opened an opportunity for key players to innovate acute myeloid leukemia (AML) therapeutics market.
The global acute myeloid leukemia (AML) therapeutics market is segmented on the basic of disease subtype, treatment type, end user and region.
Based on the disease subtype, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:
Based on treatment type, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:
Based on end user, the acute myeloid leukemia (AML) therapeutics market is segmented into the following:
The global acute myeloid leukemia (AML) therapeutics market is anticipated to show lucrative growth owing to increased investment in innovative technologies by key players. Players in this market using various strategies to fuel their global footprint and to gain a competitive edge. Product pipelines, new product launches, agreements and collaborations, acquisitions, mergers and clinical trials are some key strategies applied from global players in recent years are anticipated to give a robust hike to the market in the forecast period.
You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/16738
Geographically, acute myeloid leukemia (AML) therapeutics market is segmented into regions viz. North America, Latin America, Europe, Asia Pacific and Japan, Middle East and Africa. North America is anticipated to be major contributor to this market accounting maximum percent of share in AML therapeutics market followed by Europe. Slow but constant growth in prevalence for AML in North America is anticipated to fuel the growth in acute myeloid leukemia (AML) therapeutics market. In Asia pacific region, China and India are anticipated to show high growth in acute myeloid leukemia (AML) therapeutics market due to new developments in healthcare infrastructure in the region.
The players in acute myeloid leukemia (AML) therapeutics market include Ambit Biosciences Corporation, Celgene Corporation, Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd, Genzyme Corporation, and Sunesis Pharmaceuticals Inc., Abbvie Inc., Astellas Pharma Inc, CTI Biopharma Corp etc.
Continue reading here:
Acute Myeloid Leukemia (AML) Therapeutics Market Promising Growth Opportunities over 2017 2025 - 3rd Watch News
Bone Marrow Processing System Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario – 3rd Watch News
By daniellenierenberg
Bone marrow aspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.
Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/3184
The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.
Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/3184
In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.
<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/3184
Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.
Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others
Read more here:
Bone Marrow Processing System Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario - 3rd Watch News
CRISPR trial shows promising results for sickle cell and thalassaemia – BioNews
By daniellenierenberg
22 June 2020
CRISPRgenome editing has been successfully used to treat three patients with blood disorders in a clinical trial.
Two US patients with beta-thalassaemia and one with sickle cell disease had their bone marrow stem cells edited to produce a different form of haemoglobin, which is normally only found in fetuses and newborns.
'The results [demonstrate] that CRISPR/Cas9 gene editing has the potential to be a curative therapy for severe genetic diseases like sickle cell and beta-thalassaemia,' said Dr Reshma Kewalrami, CEO and President of Vertex, which is running the study jointly with another US pharmaceutical company, CRISPR Therapeutics.
Both sickle cell and beta-thalassaemia are caused by mutations in a gene that produces haemoglobin, the protein in red blood cells that carries oxygen throughout the body. With limited treatment options, patients are often dependent on blood transfusions.
However, the human body is able to make another form of haemoglobin, encoded in a completely separate gene, which is normally only expressed during fetal development and is switched off soon after birth.
In the clinical trial, blood stem cells were removed from the patients and a control gene that turns off the production of fetal haemoglobin was inactivated. Patients were given chemotherapy to remove remaining bone marrow stem cellsbefore they were replaced by the editedcells. The patients were then able to make fetal haemoglobin as adults.
The results of the ongoing trial, presented at the virtual Annual European Hematology Association Congress, reported that two beta-thalassaemia patients were transfusion independent at five and fifteen months after treatment, and the sickle cell patient was free from painful crises at nine months after treatment.
All three patients suffered significant side effects (from which they all recovered), but these were thought to be as a result of the chemotherapy rather than genome editing. Chemotherapy can also have long-term effects including infertility.
It is hoped that this treatment will have long-lasting and durable effects in patients with inherited blood diseases, and early clinical data appear promising. However, patients will need to be followed up throughout their lives to record any changes.
'These highly encouraging early data represent one more step toward delivering on the promise and potential of CRISPR/Cas9 therapies as a new class of potentially transformative medicines to treat serious diseases,' said Dr Samarth Kulkarni, CEO of CRISPR Therapeutics.
See original here:
CRISPR trial shows promising results for sickle cell and thalassaemia - BioNews